Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports.
Medicine (Baltimore)
November 2019
Internal Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, P.R. China.
Rationale: Anlotinib, a novel orally administered multitargeted tyrosine kinase inhibitor, inhibiting tumor angiogenesis and growth, significantly prolonged overall survival, and progression-free survival with a manageable safety profile as a third-line therapy among refractory advanced nonsmall cell lung cancer (NSCLC) patients in ALTER 0303 trail (NCT02388919).
Patient Concerns: Two squamous cell lung cancer patients with mediastinal metastasis undergoing the treatment of anlotinib developed clinical symptom of cough, which was worse upon ingestion.
Diagnoses: On the basis of patients' clinical symptoms and radiographic findings, they were diagnosed with acquired esophago-tracheobronchial fistula.
Outcome and safety of tailored surgical treatments of nonmalignant esophagotracheobronchial fistula: report of fourteen patients.
Ther Clin Risk Manag
November 2017
Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.
Introduction: Acquired benign esophageal tracheobronchial fistulae are clinically rare. In this paper, we summarize our experiences in surgical treatment of 14 consecutive patients with acquired benign esophageal tracheobronchial fistula.
Methods: This series included patients who underwent surgery between January 2002 and June 2015 at our institution.
A supposed primary and cortico-sensitive pleuropericarditis in a 33-year-old woman with an apparent recovery of 9 months, revealed an esophageal leiomyosarcoma with a fatal issue following tumoral and purulent invasion of the mediastinum with an esophagobronchial fistula. Pericardis of tumoral origin may appear as a benign cryptogenetic affection sensitive to corticotherapy. Acquired esophagotracheobronchial fistulae are usually of neoplastic origin and the prognosis is extremely severe, survival being rarely more than three months.
View Article and Find Full Text PDF[Acquired esophago-tracheo-bronchial fistulas (observations on a case)].
Arch Chir Torac Cardiovasc
August 1976
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!